Since Prior Flu Exposure Dictates Your Future Immune Response, New Vaccine Regiments Can Be Rationally Developed, Researchers Say
A team of scientists, led by researchers at The Wistar Institute, has determined that it might be possible to stimulate the immune system against multiple strains of influenza virus by sequentially vaccinating individuals with distinct influenza strains isolated over the last century.
Their results also suggest that world health experts might need to re-evaluate standard tests used for surveillance of novel influenza strains. Their findings are published in the Journal of Experimental Medicine.
According to the Wistar researchers, their analysis could lead to an alternative approach to creating a “universal” flu vaccine—a vaccine that would provide resistance to seasonal and pandemic influenza strains over many years, negating the need for an annual flu shot.
“Influenza vaccines are very safe and provide good protection. However, we need to continuously update seasonal flu vaccines because influenza viral proteins change over time,” said Scott Hensley, Ph.D., an assistant professor at The Wistar Institute and corresponding author on the study. “Since influenza viruses are constantly changing, we all have unique pre-exposure histories that depend on when we were born and the specific types of viruses that circulated during our childhood.”
Vaccines work by stimulating the immune system to produce antibody proteins against particles (called antigens) from an infectious agent, such as bacteria or a virus. The immune system saves the cells that produce effective antibodies, which then provide immunity against future attacks by the same or similar infectious agents. Despite the availability of a vaccine, seasonal influenza typically kills 36,000 Americans, alone, and nearly a half million individuals around the world, in total.
Most current efforts to create universal vaccines hinge on the idea of generating antibodies against a portion of the virus that is relatively unchanged year-to-year.
“Our studies demonstrate that individuals that are infected sequentially with dramatically different influenza strains mount antibody responses against a conserved region of influenza virus,” Hensley said. “Since we now know that pre-exposure events can influence vaccine responsiveness in a predictable way, we can begin to design vaccine regiments that preferentially elicit antibody responses against conserved regions of influenza virus.”
The researchers began their current work by studying human antibody responses against the 2009 pandemic H1N1 virus. The 2009 strain is antigenically distinct from recently circulating seasonal H1N1 strains, and a distant relative of the virus that caused the devastating “Spanish Flu” of the early 20th century. The most effective antibodies are those that bind to a particular portion (or “epitope”) of hemagglutinin (HA), a protein produced by the influenza virus.
According to Hensley, however, their chief insight occurred when his team hit the “sort” button on a spreadsheet document, thereby arranging all samples by age of the donor. Different aged people, they found, mount vastly different antibody responses to pandemic H1N1, depending on whether or not they were exposed to a seasonal H1N1 years earlier. “We can now accurately predict how individuals will respond to the pandemic H1N1 strain based on the year that they were born,” Hensley said.
Their investigation also suggests that ferrets with no prior influenza exposure might not be the most reliable predictor of human immune responses. Anti-sera—or blood containing antibodies–created in these “naïve” ferrets are commonly used for influenza surveillance. The researchers found that naïve ferrets mount a response to an epitope in a decidedly different portion of HA than do most humans, but subsequently infecting these ferrets with other historical influenza strains can shift the antibody response toward the epitope that human antibodies recognize. This shift might also be replicable in humans through multiple infections or vaccinations, the researchers believe.
According to Hensley, one strategy would be to sequentially vaccinate children with antigenically distinct viral strains. “Babies are born with an immunological blank slate,” Hensley said. “We may be able to strategically vaccinate our children with antigenically diverse influenza strains to elicit antibodies against conserved viral epitopes.”
The Latest Bing News on:
Universal Influenza Vaccine
- Emergex starts up production for universal influenza vaccineon August 1, 2022 at 2:18 am
The UK company plans to manufacture sufficient levels of its universal influenza vaccine for use in Phase I human trials.
- Could we ever eradicate the flu?on August 1, 2022 at 2:00 am
But is it possible to eradicate the flu? The short answer is no, said Mark Slifka, an immunologist at the Oregon National Primate Research Center. The closest we came to this holy grail of ...
- Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccineon July 27, 2022 at 11:22 pm
Laurens Rademacher, Chief Technology Officer at Emergex commented: “Advancing into cGMP production is an important milestone for the Emergex Universal Influenza Vaccine candidate. Having ...
- Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccineon July 27, 2022 at 11:01 pm
Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine Abingdon, Oxon, UK, 28 July 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a ...
The Latest Google Headlines on:
Universal Influenza Vaccine
The Latest Bing News on:
- What to know about monkeypox vaccination that could stretch supplieson August 6, 2022 at 6:45 am
Amid a newly announced monkeypox national public emergency and shortage of vaccines, the Food and Drug Administration announced it is reviewing a new vaccine approach that could lead to a fivefold ...
- Vanderbilt seeks volunteers for pediatric influenza vaccine studyon August 6, 2022 at 6:15 am
Researchers at Vanderbilt are hopeful that a new study will identify a nasal vaccine that is more effective in fighting the flu.
- Panama Awaits Combined Covid-Influenza Vaccineon August 5, 2022 at 9:40 pm
Panama is waiting for a combined vaccine that is currently being studied in the United States and that could be given to the population a ...
- #HEALTH: Influenza on the riseon August 4, 2022 at 5:00 pm
OVER the last two years, Covid-19 preventive measures have reduced our exposure to infectious diseases. However, as the pandemic and associated social restrictions ease globally, we are starting to ...
- A combined influenza and COVID-19 mRNA vaccineon August 3, 2022 at 6:55 pm
A combined mRNA vaccine is capable of inducing broad and durable protection against co-infection with SARS-CoV-2 and IAV, ...
- Vaxess Announces Launch of Phase 1 Trial For H1 Influenza Vaccine Patchon August 2, 2022 at 5:00 pm
Vaxess Technologies, Inc., a life sciences company developing a shelf-stable, sustained-release vaccine patch, today announced that it has laun ...
- Influenza Vaccines Market Size, Share, Growth And Trends Market Research Report To 2031on August 2, 2022 at 2:14 am
Kenneth Research recently added a report on ' Influenza Vaccines Market' in its database of market research reports which provides its readers an ...
- The influenza vaccine safe for Cardiovascular patients- finds study.on August 1, 2022 at 6:45 am
As per the recent study results, Influenza vaccination is safe and efficacious for reducing cardiovascular morbidities and mortalities in patients with Myocardial Infarction. The study ...
- GSK to supply 85 million doses of pandemic influenza vaccine to EUon July 29, 2022 at 4:39 pm
The company has signed a contract for the reservation of future production and supply of its pandemic influenza vaccine, Adjupanrix, to support pandemic preparedness in Europe ...
- Avisena administers influenza vaccine to SAS students, staffon July 29, 2022 at 2:59 am
Avisena Healthcare Sdn Bhd (Avisena) today administered influenza vaccines to approximately 560 students and employees of Sekolah Sultan Alam Shah (SAS) Putrajaya here, via its influenza vaccination ...